Brokerages Set Zimmer Biomet Holdings, Inc. (NYSE:ZBH) PT at $107.50

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been assigned an average recommendation of “Hold” from the twenty-two brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $107.50.

ZBH has been the topic of several recent research reports. UBS Group lowered their target price on shares of Zimmer Biomet from $96.00 to $88.00 and set a “sell” rating on the stock in a research note on Thursday, November 6th. BTIG Research lowered their price target on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Redburn Partners set a $130.00 price objective on shares of Zimmer Biomet in a report on Thursday, September 18th. Canaccord Genuity Group lowered their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a report on Monday, November 10th. Finally, Baird R W lowered Zimmer Biomet from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 16th.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $90.78 on Friday. The stock has a 50 day moving average of $94.07 and a two-hundred day moving average of $96.58. Zimmer Biomet has a 12 month low of $85.33 and a 12 month high of $114.44. The firm has a market cap of $17.99 billion, a P/E ratio of 22.47, a price-to-earnings-growth ratio of 2.39 and a beta of 0.61. The company has a current ratio of 2.43, a quick ratio of 1.39 and a debt-to-equity ratio of 0.59.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm had revenue of $2 billion for the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, analysts expect that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, December 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZBH. Key Financial Inc increased its position in Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. boosted its holdings in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in shares of Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 149 shares during the period. Root Financial Partners LLC acquired a new stake in shares of Zimmer Biomet during the 3rd quarter worth approximately $31,000. Finally, Mather Group LLC. purchased a new stake in shares of Zimmer Biomet during the 3rd quarter valued at approximately $36,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.